APA (7th ed.) Citation

Lluís Puig, Mark Lomaga, Kristin Hollister, Yves Dutronc, Lovisa Berggren, & Peter C.M. van de Kerkhof. (2020). An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis. Medical Journals Sweden.

Chicago Style (17th ed.) Citation

Lluís Puig, Mark Lomaga, Kristin Hollister, Yves Dutronc, Lovisa Berggren, and Peter C.M. van de Kerkhof. An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis. Medical Journals Sweden, 2020.

MLA (9th ed.) Citation

Lluís Puig, et al. An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis. Medical Journals Sweden, 2020.